CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

The U.S. secured a partial judgment in its favor on claims that CVS’s pharmacy benefit management subsidiary, Caremark, ...

CVS Caremark has been ordered to pay $95 million after a federal judge found the pharmacy benefit manager improperly inflated Medicare Part D drug prices by failing to report required pharmacy ...

Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing competition in ...

If Caremark does not pay millions it says it’s owed, the plan may need to require every active member to pay an additional $100 in annual premiums starting in 2026.

The Treasurer's Office said in a news release Thursday that 18 months of contract negotiations have resulted in “an untenable impasse" with CVS Caremark, "which potentially endangers the ...

Weight loss drugs like Wegovy and Zepbound are getting cheaper, ... CVS Caremark announced that it will now cover Wegovy under its pharmacy benefit plans — but it will no longer cover Zepbound.

Cabandugama said many of his patients typically paid around $1,500 a month out of pocket for brand names Wegovy and Zepbound, but in recent months they’ve been able to get the same doses for ...